Your browser doesn't support javascript.
loading
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko, Justin M; Giltnane, Jennifer M; Wang, Kai; Schwarz, Luis J; Young, Christian D; Cook, Rebecca S; Owens, Phillip; Sanders, Melinda E; Kuba, Maria G; Sánchez, Violeta; Kurupi, Richard; Moore, Preston D; Pinto, Joseph A; Doimi, Franco D; Gómez, Henry; Horiuchi, Dai; Goga, Andrei; Lehmann, Brian D; Bauer, Joshua A; Pietenpol, Jennifer A; Ross, Jeffrey S; Palmer, Gary A; Yelensky, Roman; Cronin, Maureen; Miller, Vincent A; Stephens, Phillip J; Arteaga, Carlos L.
Afiliación
  • Balko JM; Departments of 1Medicine, 2Pathology, Microbiology & Immunology, 3Cancer Biology, and 4Biochemistry; 5Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; Departments of 6Cell & Tissue Biology and 7Medicine, University of California, San Francisco, San Francisco, California; 8Foundation Medicine, Cambridge, Massachusetts; 9Oncosalud; and 10Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú
Cancer Discov ; 4(2): 232-45, 2014 Feb.
Article en En | MEDLINE | ID: mdl-24356096
UNLABELLED: Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In patients lacking a pCR, NAC selects a subpopulation of chemotherapy-resistant tumor cells. To understand the molecular underpinnings driving treatment-resistant TNBCs, we performed comprehensive molecular analyses on the residual disease of 74 clinically defined TNBCs after NAC, including next-generation sequencing (NGS) on 20 matched pretreatment biopsies. Combined NGS and digital RNA expression analysis identified diverse molecular lesions and pathway activation in drug-resistant tumor cells. Ninety percent of the tumors contained a genetic alteration potentially treatable with a currently available targeted therapy. Thus, profiling residual TNBCs after NAC identifies targetable molecular lesions in the chemotherapy-resistant component of the tumor, which may mirror micrometastases destined to recur clinically. These data can guide biomarker-driven adjuvant studies targeting these micrometastases to improve the outcome of patients with TNBC who do not respond completely to NAC. SIGNIFICANCE: This study demonstrates the spectrum of genomic alterations present in residual TNBC after NAC. Because TNBCs that do not achieve a CR after NAC are likely to recur as metastatic disease at variable times after surgery, these alterations may guide the selection of targeted therapies immediately after mastectomy before these metastases become evident.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Perfilación de la Expresión Génica / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Cancer Discov Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Perfilación de la Expresión Génica / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Cancer Discov Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos